BDTX
HEALTHCAREBlack Diamond Therapeutics Inc
$2.82-0.05 (-1.74%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BDTX Today?
No stock-specific AI insight has been generated for BDTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.61$4.94
$2.82
Fundamentals
Market Cap$162M
P/E Ratio7.2
EPS$0.39
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin0.3%
Debt / Equity—
Trading
Volume993K
Avg Volume (10D)—
Shares Outstanding57.3M
BDTX News
21 articles- Black Diamond Therapeutics | 8-K: Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMoomoo·May 9, 2026
- Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 7, 2026
- Implied Volatility Surging for Black Diamond Therapeutics Stock OptionsYahoo Finance·Apr 28, 2026
- BDTX and the CNS-Active EGFR Trend: Why C797S Is the PrizeYahoo Finance·Apr 23, 2026
- BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go RightYahoo Finance·Apr 23, 2026
- Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and RisksYahoo Finance·Apr 23, 2026
- Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual MeetingYahoo Finance·Apr 21, 2026
- Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?Yahoo Finance·Apr 15, 2026
- BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026Yahoo Finance·Apr 9, 2026
- Black Diamond Stock: Weighing Catalysts vs. ConcentrationYahoo Finance·Apr 9, 2026
- BDTX: What Silevertinib Data Say About EGFR NSCLC UpsideYahoo Finance·Apr 9, 2026
- Wedbush Bullish on Black Diamond Therapeutics (BDTX) Following Progress in Silevertinib ProgramYahoo Finance·Mar 25, 2026
- Black Diamond: Q4 Earnings SnapshotYahoo Finance·Mar 16, 2026
- Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 16, 2026
- DAWN Stock Jumps 66% on $2.5B Buyout Offer From ServierYahoo Finance·Mar 9, 2026
- Black Diamond Therapeutics Teases Next-Quarter PFS Data for Silevertinib at TD Cowen ConferenceMarketbeat·Mar 6, 2026
- Black Diamond Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Mar 2, 2026
- Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst TrackerYahoo Finance·Feb 2, 2026
- Convergent Therapeutics Appoints Elizabeth L. Montgomery Chief People OfficerYahoo Finance·Jan 28, 2026
- Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?Yahoo Finance·Jan 23, 2026
- Declining Stock and Solid Fundamentals: Is The Market Wrong About Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)?Yahoo Finance·Jan 16, 2026
All 21 articles loaded
Price Data
Open$2.93
Previous Close$2.87
Day High$2.97
Day Low$2.82
52 Week High$4.94
52 Week Low$1.61
52-Week Range
$1.61$4.94
$2.82
Fundamentals
Market Cap$162M
P/E Ratio7.2
EPS$0.39
Dividend Yield—
Dividend / Share—
ROE0.2%
Profit Margin0.3%
Debt / Equity—
Trading
Volume993K
Avg Volume (10D)—
Shares Outstanding57.3M
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—